Table of Content
1. INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2. MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 SALES VOLUME
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES MARKET : RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3. MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
6. EPIDEMIOLOGY
7. PIPELINE ANALYSIS
7.1 PHASE III CANDIDATES
7.2 PHASE II CANDIDATES
7.3 PHASE I CANDIDATES
7.4 OTHERS (PRE-CLINICAL AND RESEARCH)
8. INDUSTRY INSIGHTS
8.1 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
8.2 KEY PRICING STRATEGIES
8.3 KEY PATIENT ENROLLMENT STRATEGIES
8.4 INTERVIEWS WITH ONCOLOGISTS
8.5 INTERVIEWS WITH INSTRUMENT MANUFACTURERS
8.6 OTHER KOL SNAPSHOTS
9. REGULATOTY FRAMEWORK
10. TECHNOOGY ADVNCEMTL
11. COMPETITION
12. GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES MARKET , BY TREATMENT TYPE
12.1 OVERVIEW
12.2 TRADITIONAL DRUGS
12.2.1 CORTICOSTEROIDS
12.2.1.1. FLUOROHYDROCORTISONE
12.2.1.1.1. MARKET VALUE (USD MILLION)
12.2.1.1.2. MARKET VOLUME (UNITS)
12.2.1.1.3. AVERAGE SELLING PRICE (USD)
12.2.1.2. PREDNISOLONE
12.2.1.2.1. MARKET VALUE (USD MILLION)
12.2.1.2.2. MARKET VOLUME (UNITS)
12.2.1.2.3. AVERAGE SELLING PRICE (USD)
12.2.1.3. METHYLPREDNISOLON
12.2.1.3.1. MARKET VALUE (USD MILLION)
12.2.1.3.2. MARKET VOLUME (UNITS)
12.2.1.3.3. AVERAGE SELLING PRICE (USD)
12.2.1.4. DEXAMETHASONE
12.2.1.4.1. MARKET VALUE (USD MILLION)
12.2.1.4.2. MARKET VOLUME (UNITS)
12.2.1.4.3. AVERAGE SELLING PRICE (USD)
12.2.1.5. BETAMETHASONE
12.2.1.5.1. MARKET VALUE (USD MILLION)
12.2.1.5.2. MARKET VOLUME (UNITS)
12.2.1.5.3. AVERAGE SELLING PRICE (USD)
12.2.1.6. OTHERS
12.2.2 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
12.2.2.1. IBUPROFEN
12.2.2.1.1. MARKET VALUE (USD MILLION)
12.2.2.1.2. MARKET VOLUME (UNITS)
12.2.2.1.3. AVERAGE SELLING PRICE (USD)
12.2.2.2. NAPROXEN
12.2.2.2.1. MARKET VALUE (USD MILLION)
12.2.2.2.2. MARKET VOLUME (UNITS)
12.2.2.2.3. AVERAGE SELLING PRICE (USD)
12.2.2.3. DICLOFENAC
12.2.2.3.1. MARKET VALUE (USD MILLION)
12.2.2.3.2. MARKET VOLUME (UNITS)
12.2.2.3.3. AVERAGE SELLING PRICE (USD)
12.2.2.4. CELECOXIB
12.2.2.4.1. MARKET VALUE (USD MILLION)
12.2.2.4.2. MARKET VOLUME (UNITS)
12.2.2.4.3. AVERAGE SELLING PRICE (USD)
12.2.2.5. MEFENAMIC ACID
12.2.2.5.1. MARKET VALUE (USD MILLION)
12.2.2.5.2. MARKET VOLUME (UNITS)
12.2.2.5.3. AVERAGE SELLING PRICE (USD)
12.2.2.6. ETORICOXIB
12.2.2.6.1. MARKET VALUE (USD MILLION)
12.2.2.6.2. MARKET VOLUME (UNITS)
12.2.2.6.3. AVERAGE SELLING PRICE (USD)
12.2.2.7. OTHERS
12.3 BIOLOGICS
12.3.1 INFLIXIMAB
12.3.1.1. MARKET VALUE (USD MILLION)
12.3.1.2. MARKET VOLUME (UNITS)
12.3.1.3. AVERAGE SELLING PRICE (USD)
12.3.2 ETANERCEPT
12.3.2.1. MARKET VALUE (USD MILLION)
12.3.2.2. MARKET VOLUME (UNITS)
12.3.2.3. AVERAGE SELLING PRICE (USD)
12.3.3 ADALIMUMAB
12.3.3.1. MARKET VALUE (USD MILLION)
12.3.3.2. MARKET VOLUME (UNITS)
12.3.3.3. AVERAGE SELLING PRICE (USD)
12.3.4 RITUXIMAB
12.3.4.1. MARKET VALUE (USD MILLION)
12.3.4.2. MARKET VOLUME (UNITS)
12.3.4.3. AVERAGE SELLING PRICE (USD)
12.3.5 ABATACEPT
12.3.5.1. MARKET VALUE (USD MILLION)
12.3.5.2. MARKET VOLUME (UNITS)
12.3.5.3. AVERAGE SELLING PRICE (USD)
12.3.6 EFALIZUMAB
12.3.6.1. MARKET VALUE (USD MILLION)
12.3.6.2. MARKET VOLUME (UNITS)
12.3.6.3. AVERAGE SELLING PRICE (USD)
12.3.7 OTHERS
12.4 NOVEL THERAPIES
12.4.1 (IL)-17
12.4.1.1. SECUKINUMAB
12.4.1.1.1. MARKET VALUE (USD MILLION)
12.4.1.1.2. MARKET VOLUME (UNITS)
12.4.1.1.3. AVERAGE SELLING PRICE (USD)
12.4.1.2. IXEKIZUMAB
12.4.1.2.1. MARKET VALUE (USD MILLION)
12.4.1.2.2. MARKET VOLUME (UNITS)
12.4.1.2.3. AVERAGE SELLING PRICE (USD)
12.4.1.3. BIMEKIZUMAB
12.4.1.3.1. MARKET VALUE (USD MILLION)
12.4.1.3.2. MARKET VOLUME (UNITS)
12.4.1.3.3. AVERAGE SELLING PRICE (USD)
12.4.2 IL-17R (BRODALUMAB)
12.4.2.1. MARKET VALUE (USD MILLION)
12.4.2.2. MARKET VOLUME (UNITS)
12.4.2.3. AVERAGE SELLING PRICE (USD)
12.4.3 IL-12/23P40
12.4.3.1. USTEKINUMAB
12.4.3.1.1. MARKET VALUE (USD MILLION)
12.4.3.1.2. MARKET VOLUME (UNITS)
12.4.3.1.3. AVERAGE SELLING PRICE (USD)
12.4.3.2. BRIAKINUMAB
12.4.3.2.1. MARKET VALUE (USD MILLION)
12.4.3.2.2. MARKET VOLUME (UNITS)
12.4.3.2.3. AVERAGE SELLING PRICE (USD)
12.4.4 IL-23P19
12.4.4.1. GUSELKUMAB
12.4.4.1.1. MARKET VALUE (USD MILLION)
12.4.4.1.2. MARKET VOLUME (UNITS)
12.4.4.1.3. AVERAGE SELLING PRICE (USD)
12.4.4.2. TILDRAKIZUMAB
12.4.4.2.1. MARKET VALUE (USD MILLION)
12.4.4.2.2. MARKET VOLUME (UNITS)
12.4.4.2.3. AVERAGE SELLING PRICE (USD)
12.4.4.3. BRAZIKUMAB
12.4.4.3.1. MARKET VALUE (USD MILLION)
12.4.4.3.2. MARKET VOLUME (UNITS)
12.4.4.3.3. AVERAGE SELLING PRICE (USD)
12.4.4.4. RISANKIZUMAB
12.4.4.4.1. MARKET VALUE (USD MILLION)
12.4.4.4.2. MARKET VOLUME (UNITS)
12.4.4.4.3. AVERAGE SELLING PRICE (USD)
12.4.4.5. MIRIKIZUMAB
12.4.4.5.1. MARKET VALUE (USD MILLION)
12.4.4.5.2. MARKET VOLUME (UNITS)
12.4.4.5.3. AVERAGE SELLING PRICE (USD)
12.4.4.6. OTHERS
13. GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES MARKET , BY INDICATION
13.1 OVERVIEW
13.2 ASTHMA
13.3 CHRONIC OBSTRUCTIVE PULMONARY DISEASES (COPD)
13.4 INFLAMMATORY BOWEL DISEASE (IBD)
13.5 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
13.6 RHEUMATOID ARTHRITIS (RA)
13.7 ACUTE ANTERIOR UVEITIS (AAU)
13.8 INFLAMMATORY BOWEL DISEASE (IBD)
13.9 INCLUDING CROHN’S DISEASE (CD)
13.10 ULCERATIVE COLITIS
13.11 PSORIASIS
13.12 POLYMYOSITIS (PM)
13.13 DERMATOMYOSITIS (DMTIS)
13.14 THROMBOANGIITIS OBLITERANS (TAO)
13.15 BEHCET’S DISEASE (BD)
13.16 SARCOIDOSIS
13.17 PEMPHIGUS
13.18 VITILIGO
13.19 OTHERS
14. GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES MARKET , BY DRUG TYPE
14.1 OVERVIEW
14.2 BRANDED
14.2.1 MABTHERA
14.2.2 INFLIXIMAB
14.2.3 ADALIMUMAB
14.2.4 ETANERCEPT
14.2.5 ADALIMUMAB
14.2.6 RITUXIMAB
14.2.7 ABATACEPT
14.2.8 VEDOLIZUMAB
14.2.9 USTEKINUMAB
14.2.10 TOFACITINIB
14.2.11 OZANIMOD
14.2.12 UPADACITINIB
14.2.13 OTHERS
14.3 GENERIC
15. GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES MARKET , BY FORM
15.1 OVERVIEW
15.2 TABLET
15.3 CAPSULES
15.4 LIQUID
15.5 GEL
15.6 OTHERS
16. GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES MARKET , BY ROUTE OF ADMINISTRATION
16.1 OVERVIEW
16.2 ORAL
16.3 INTRAVENOUS
16.4 OTHERS
17. GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES MARKET , BY END USER
17.1 OVERVIEW
17.2 HOSPITALS
17.3 SPECIALTY CLINICS
17.4 OTHERS
18. GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES MARKET , BY DISTRIBUTION CHANNEL
18.1 OVERVIEW
18.2 HOSPITAL PHARMACY
18.3 RETAIL PHARMACY
18.4 ONLINE PHARMACY
18.5 OTHERS
19. GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES MARKET , BY REGION
GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES MARKET , (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
19.1 NORTH AMERICA
19.1.1 U.S.
19.1.2 CANADA
19.1.3 MEXICO
19.2 EUROPE
19.2.1 GERMANY
19.2.2 FRANCE
19.2.3 U.K.
19.2.4 ITALY
19.2.5 SPAIN
19.2.6 RUSSIA
19.2.7 TURKEY
19.2.8 BELGIUM
19.2.9 DENMARK
19.2.10 NETHERLANDS
19.2.11 SWITZERLAND
19.2.12 SWEDEN
19.2.13 POLAND
19.2.14 NORWAY
19.2.15 FINLAND
19.2.16 REST OF EUROPE
19.3 ASIA-PACIFIC
19.3.1 JAPAN
19.3.2 CHINA
19.3.3 SOUTH KOREA
19.3.4 INDIA
19.3.5 AUSTRALIA
19.3.6 NEW ZEALAND
19.3.7 SINGAPORE
19.3.8 THAILAND
19.3.9 MALAYSIA
19.3.10 VIETNAM
19.3.11 TAIWAN
19.3.12 INDONESIA
19.3.13 PHILIPPINES
19.3.14 REST OF ASIA-PACIFIC
19.4 SOUTH AMERICA
19.4.1 BRAZIL
19.4.2 ARGENTINA
19.4.3 REST OF SOUTH AMERICA
19.5 MIDDLE EAST AND AFRICA
19.5.1 SOUTH AFRICA
19.5.2 SAUDI ARABIA
19.5.3 BAHRAIN
19.5.4 UAE
19.5.5 KUWAIT
19.5.6 OMAN
19.5.7 QATAR
19.5.8 EGYPT
19.5.9 ISRAEL
19.5.10 REST OF MIDDLE EAST AND AFRICA
19.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
20. GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES MARKET ,COMPANY LANDSCAPE
20.1 COMPANY SHARE ANALYSIS: GLOBAL
20.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
20.3 COMPANY SHARE ANALYSIS: EUROPE
20.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
20.5 MERGERS & ACQUISITIONS
20.6 NEW PRODUCT DEVELOPMENT & APPROVALS
20.7 EXPANSIONS
20.8 REGULATORY CHANGES
20.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
21. GLOBAL IMMUNE-MEDIATED INFLAMMATORY DISEASES MARKET , COMPANY PROFILE
21.1 AMGEN INC
21.1.1 COMPANY OVERVIEW
21.1.2 REVENUE ANALYSIS
21.1.3 GEOGRAPHIC PRESENCE
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENTS
21.2 EPITOGENESIS, INC.
21.2.1 COMPANY OVERVIEW
21.2.2 REVENUE ANALYSIS
21.2.3 GEOGRAPHIC PRESENCE
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 JANSSEN BIOTECH, INC.
21.3.1 COMPANY OVERVIEW
21.3.2 REVENUE ANALYSIS
21.3.3 GEOGRAPHIC PRESENCE
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENTS
21.4 ABBOTT
21.4.1 COMPANY OVERVIEW
21.4.2 REVENUE ANALYSIS
21.4.3 GEOGRAPHIC PRESENCE
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENTS
21.5 F. HOFFMANN-LA ROCHE LTD
21.5.1 COMPANY OVERVIEW
21.5.2 REVENUE ANALYSIS
21.5.3 GEOGRAPHIC PRESENCE
21.5.4 PRODUCT PORTFOLIO
21.5.5 RECENT DEVELOPMENTS
21.6 BIOGEN
21.6.1 COMPANY OVERVIEW
21.6.2 REVENUE ANALYSIS
21.6.3 GEOGRAPHIC PRESENCE
21.6.4 PRODUCT PORTFOLIO
21.6.5 RECENT DEVELOPMENTS
21.7 BRISTOL-MYERS SQUIBB COMPANY.
21.7.1 COMPANY OVERVIEW
21.7.2 REVENUE ANALYSIS
21.7.3 GEOGRAPHIC PRESENCE
21.7.4 PRODUCT PORTFOLIO
21.7.5 RECENT DEVELOPMENTS
21.8 PFIZER INC
21.8.1 COMPANY OVERVIEW
21.8.2 REVENUE ANALYSIS
21.8.3 GEOGRAPHIC PRESENCE
21.8.4 PRODUCT PORTFOLIO
21.8.5 RECENT DEVELOPMENTS
21.9 ABBVIE INC
21.9.1 COMPANY OVERVIEW
21.9.2 REVENUE ANALYSIS
21.9.3 GEOGRAPHIC PRESENCE
21.9.4 PRODUCT PORTFOLIO
21.9.5 RECENT DEVELOPMENTS
21.10 NOVARTIS AG
21.10.1 COMPANY OVERVIEW
21.10.2 REVENUE ANALYSIS
21.10.3 GEOGRAPHIC PRESENCE
21.10.4 PRODUCT PORTFOLIO
21.10.5 RECENT DEVELOPMENTS
21.11 BOEHRINGER INGELHEIM INTERNATIONAL GMBH.
21.11.1 COMPANY OVERVIEW
21.11.2 REVENUE ANALYSIS
21.11.3 GEOGRAPHIC PRESENCE
21.11.4 PRODUCT PORTFOLIO
21.11.5 RECENT DEVELOPMENTS
21.12 MERCK & CO INC.
21.12.1 COMPANY OVERVIEW
21.12.2 REVENUE ANALYSIS
21.12.3 GEOGRAPHIC PRESENCE
21.12.4 PRODUCT PORTFOLIO
21.12.5 RECENT DEVELOPMENTS
21.13 SUN PHARMACEUTICAL INDUSTRIES LTD.
21.13.1 COMPANY OVERVIEW
21.13.2 REVENUE ANALYSIS
21.13.3 GEOGRAPHIC PRESENCE
21.13.4 PRODUCT PORTFOLIO
21.13.5 RECENT DEVELOPMENTS
21.14 TEVA PHARMACEUTICALS INDUSTRIES LTD
21.14.1 COMPANY OVERVIEW
21.14.2 REVENUE ANALYSIS
21.14.3 GEOGRAPHIC PRESENCE
21.14.4 PRODUCT PORTFOLIO
21.14.5 RECENT DEVELOPMENTS
21.15 ASTRAZENECA
21.15.1 COMPANY OVERVIEW
21.15.2 REVENUE ANALYSIS
21.15.3 GEOGRAPHIC PRESENCE
21.15.4 PRODUCT PORTFOLIO
21.15.5 RECENT DEVELOPMENTS
21.16 AMPIO PHARMACEUTICALS INC
21.16.1 COMPANY OVERVIEW
21.16.2 REVENUE ANALYSIS
21.16.3 GEOGRAPHIC PRESENCE
21.16.4 PRODUCT PORTFOLIO
21.16.5 RECENT DEVELOPMENTS
21.17 LILLY
21.17.1 COMPANY OVERVIEW
21.17.2 REVENUE ANALYSIS
21.17.3 GEOGRAPHIC PRESENCE
21.17.4 PRODUCT PORTFOLIO
21.17.5 RECENT DEVELOPMENTS
21.18 ZYDUS GROUP
21.18.1 COMPANY OVERVIEW
21.18.2 REVENUE ANALYSIS
21.18.3 GEOGRAPHIC PRESENCE
21.18.4 PRODUCT PORTFOLIO
21.18.5 RECENT DEVELOPMENTS
21.19 AKORN, INCORPORATED
21.19.1 COMPANY OVERVIEW
21.19.2 REVENUE ANALYSIS
21.19.3 GEOGRAPHIC PRESENCE
21.19.4 PRODUCT PORTFOLIO
21.19.5 RECENT DEVELOPMENTS
21.20 DAIICHI SANKYO COMPANY, LIMITED
21.20.1 COMPANY OVERVIEW
21.20.2 REVENUE ANALYSIS
21.20.3 GEOGRAPHIC PRESENCE
21.20.4 PRODUCT PORTFOLIO
21.20.5 RECENT DEVELOPMENTS
21.21 APOTEX INC
21.21.1 COMPANY OVERVIEW
21.21.2 REVENUE ANALYSIS
21.21.3 GEOGRAPHIC PRESENCE
21.21.4 PRODUCT PORTFOLIO
21.21.5 RECENT DEVELOPMENTS
21.22 ELAM PHARMA PVT. LTD.
21.22.1 COMPANY OVERVIEW
21.22.2 REVENUE ANALYSIS
21.22.3 GEOGRAPHIC PRESENCE
21.22.4 PRODUCT PORTFOLIO
21.22.5 RECENT DEVELOPMENTS
21.23 ADVACARE PHARMA
21.23.1 COMPANY OVERVIEW
21.23.2 REVENUE ANALYSIS
21.23.3 GEOGRAPHIC PRESENCE
21.23.4 PRODUCT PORTFOLIO
21.23.5 RECENT DEVELOPMENTS
21.24 ANANT PHARMACEUTICALS PVT. LTD.
21.24.1 COMPANY OVERVIEW
21.24.2 REVENUE ANALYSIS
21.24.3 GEOGRAPHIC PRESENCE
21.24.4 PRODUCT PORTFOLIO
21.24.5 RECENT DEVELOPMENTS
22. RELATED REPORTS
23. CONCLUSION
24. QUESTIONNAIRE
25. ABOUT DATA BRIDGE MARKET RESEARCH
